Inc. reports the peptide could damage neurons in lab tests, though its role in people with Alzheimer's has not been shown.
Recap by typeshit. Full story at Inc.com on MSN.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
A short explainer for newcomers placing Ozempic, Wegovy, Mounjaro and Zepbound in the same molecule family that health and longevity circles keep discussing.
Dr Morse claims the drug's base chain is 39 amino acids and that two added side chains push it past the 40 amino acid biologic threshold. His take, not an FDA finding.
Loading…